COVID-19 and diabetes mellitus: how one pandemic worsens the other

dc.contributor.authorAzar, William S.
dc.contributor.authorNjeim, Rachel
dc.contributor.authorFares, Angie H.
dc.contributor.authorAzar, Nadim S.
dc.contributor.authorAzar, Sami T.
dc.contributor.authorEl Sayed, Mazen J.
dc.contributor.authorEid, Assaad A.
dc.contributor.departmentAnatomy, Cell Biology, and Physiological Sciences
dc.contributor.departmentInternal Medicine
dc.contributor.departmentEmergency Medicine
dc.contributor.departmentDiabetes Program
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:36:52Z
dc.date.available2025-01-24T11:36:52Z
dc.date.issued2020
dc.description.abstractIn light of the most challenging public health crisis of modern history, COVID-19 mortality continues to rise at an alarming rate. Patients with co-morbidities such as hypertension, cardiovascular disease, and diabetes mellitus (DM) seem to be more prone to severe symptoms and appear to have a higher mortality rate. In this review, we elucidate suggested mechanisms underlying the increased susceptibility of patients with diabetes to infection with SARS-CoV-2 with a more severe COVID-19 disease. The worsened prognosis of COVID-19 patients with DM can be attributed to a facilitated viral uptake assisted by the host’s receptor angiotensin-converting enzyme 2 (ACE2). It can also be associated with a higher basal level of pro-inflammatory cytokines present in patients with diabetes, which enables a hyperinflammatory “cytokine storm” in response to the virus. This review also suggests a link between elevated levels of IL-6 and AMPK/mTOR signaling pathway and their role in exacerbating diabetes-induced complications and insulin resistance. If further studied, these findings could help identify novel therapeutic intervention strategies for patients with diabetes comorbid with COVID-19. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.
dc.identifier.doihttps://doi.org/10.1007/s11154-020-09573-6
dc.identifier.eid2-s2.0-85088867394
dc.identifier.pmid32743793
dc.identifier.urihttp://hdl.handle.net/10938/28742
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofReviews in Endocrine and Metabolic Disorders
dc.sourceScopus
dc.subjectAdenosine monophosphate kinase (ampk)
dc.subjectAngiotensin-converting enzyme 2
dc.subjectCovid-19
dc.subjectCytokine storm
dc.subjectDiabetes mellitus
dc.subjectMechanistic target of rapamycin (mtor)
dc.subjectComorbidity
dc.subjectCoronavirus infections
dc.subjectDisease susceptibility
dc.subjectHumans
dc.subjectPandemics
dc.subjectPneumonia, viral
dc.subjectAngiotensin converting enzyme 2
dc.subjectHydroxymethylglutaryl coenzyme a reductase kinase
dc.subjectInterleukin 6
dc.subjectMammalian target of rapamycin
dc.subjectCoronavirus disease 2019
dc.subjectDisease course
dc.subjectHuman
dc.subjectImmune response
dc.subjectLung injury
dc.subjectMtor signaling
dc.subjectPandemic
dc.subjectPathogenesis
dc.subjectPrognosis
dc.subjectReview
dc.subjectRisk factor
dc.subjectSevere acute respiratory syndrome coronavirus 2
dc.subjectCoronavirus infection
dc.subjectDisease predisposition
dc.subjectImmunology
dc.subjectVirus pneumonia
dc.titleCOVID-19 and diabetes mellitus: how one pandemic worsens the other
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2020-6486.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format